...pivotal trial of its lead therapy targeting EBV-positive lymphomas.By merging with Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), Viracta Therapeutics Inc....
...Monday.TARGETSBtk – Bruton’s tyrosine kinaseEBV - Epstein-Barr virusPDK1 - Pyruvate dehydrogenase kinase 1 Paul Bonanos VRx-3996, chr-3996, Tractinostat Viracta Therapeutics Inc. Sunesis...

...Smethurst will become interim CMO. He succeeds Lisa Rojkjaer, who is joining precision oncology company Viracta Therapeutics Inc....
...Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic Nanovector ASA Viracta Therapeutics Inc. Bioventus...

...Don Elsey as CFO. He was CFO of Senseonics Inc. (Germantown, Md.). Viral-associated cancers company Viracta Therapeutics Inc....

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif...
...latent viral proteins that make cancerous cells vulnerable to antiviral treatment (see “Viral Vulnerability” ). Viracta Therapeutics Inc....
...Calif. Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294), Guangdong, China Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta Therapeutics Inc. Histone...

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif...
...cells vulnerable to antiviral treatment (see “Viral Vulnerability” ). Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta Therapeutics Inc. Histone...

...Longenecker as interim CEO. Longenecker was president and CEO at HemaQuest Pharmaceuticals Inc., which became Viracta Therapeutics Inc....

...duration of response, progression-free survival (PFS) and pharmacokinetics. VRx-3996 is an histone deacetylase (HDAC) inhibitor. Viracta Therapeutics Inc....
...duration of response, progression-free survival (PFS) and pharmacokinetics Status: Phase Ib/II started Milestone: NA Alicia Parker VRx-3996, chr-3996 Viracta Therapeutics Inc. Histone...

...syndrome (MDS) Phase I/II $26.5 Amgen Ventures; Clarus; Frazier Healthcare; Merck Research Labs Ventures Fund Viracta Therapeutics Inc....

...By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor...
...linked to IL-2 that has completed Phase II in advanced bladder cancer. Virginia Li, Staff Writer VRx-3996 NantKwest Inc. Viracta Therapeutics Inc. HDAC...

...lymphoma. Viracta Therapeutics Inc. , San Diego, Calif. NantKwest Inc. (NASDAQ:NK), San Diego, Calif. Business: Cancer Julian Zhu VRx-3996 NantKwest Inc. Viracta Therapeutics Inc....